THE USE OF DACLIZUMAB AND MYCOPHENOLATE MOFETIL IN COMBINATION WITH CORTICOSTEROIDS AND CYCLOSPORINE (LOW DOSE VERSUS LOW DOSE FOLLOWED BY WITHDRAWAL) TO OPTIMIZE RENAL FUNCTION IN RECIPIENTS OF RENAL ALLOGRAFTS